Central Retinal Artery Occlusion (CRAO): Disease Characteristics Research Report

Executive summary

Central retinal artery occlusion (CRAO) is an acute, usually painless, monocular vision-loss emergency caused by interruption of blood flow through the central retinal artery, producing ischemic injury to the inner retina and carrying substantial near-term risk for systemic vascular events (ischemic stroke, myocardial infarction). Contemporary expert consensus increasingly frames CRAO as “a stroke of the eye,” advocating urgent stroke-center evaluation and aggressive secondary prevention, while definitive, broadly endorsed acute vision-restoring therapy remains unproven and is under active clinical-trial evaluation. (chen2024centralretinalartery pages 1-2, chen2024centralretinalartery pages 4-4, fawzi2020retinalandophthalmic pages 15-17)

Key quantitative highlights (2023–2024 prioritized)

Table: This table compiles the most actionable quantitative findings for central retinal artery occlusion, including incidence, prognosis, vascular risk, treatment timing/effects, and diagnostic frequencies. It is useful as a compact evidence map for clinical and knowledge-base curation.

1. Disease information

1.1 Concise overview (current understanding)

CRAO is an ophthalmic vascular occlusion characterized by partial or complete obstruction of the central retinal artery (CRA), resulting in acute retinal ischemia and profound vision loss. The American Academy of Ophthalmology (AAO) Preferred Practice Pattern defines CRAO as “partial/complete obstruction of the central retinal artery.” (fawzi2020retinalandophthalmic pages 8-10)

A 2024 clinical review explicitly frames the condition as analogous to brain stroke: “Central retinal artery occlusion (CRAO), like a stroke in the brain, is a critical eye condition that requiring urgent medical attention.” (chen2024centralretinalartery pages 1-2)

1.2 Key identifiers

• ICD-10-CM (examples and laterality-specific codes): The AAO Preferred Practice Pattern lists ICD-10-CM codes for retinal/ophthalmic artery occlusions, including laterality-coded CRAO entries (e.g., H34.11* series for central RAO depending on laterality) and related subtypes (arterial branch occlusion H34.231; partial retinal artery occlusion H34.211; transient retinal artery occlusion H34.01). (fawzi2020retinalandophthalmic pages 22-26)
• ICD-10 (Korea HIRA claims study): CRAO is captured as H34.1 in a nationwide incidence study using administrative claims. (park2024incidenceratesof pages 1-2)
• MeSH: The AAO Preferred Practice Pattern describes its evidence searches using “retinal artery occlusion” as a MeSH major topic (e.g., “retinal artery occlusion”[MeSH Major Topic]). (fawzi2020retinalandophthalmic pages 22-26)
• MONDO ID: Not identified in the retrieved primary/secondary literature excerpts in this run; therefore not reportable with evidence-grade traceability here.

1.3 Synonyms and alternative names

• Central retinal artery occlusion (CRAO) (fawzi2020retinalandophthalmic pages 8-10)
• Retinal artery occlusion (RAO; umbrella term) (fawzi2020retinalandophthalmic pages 8-10, yu2024retinalarteryocclusion pages 1-2)
• “Stroke of the eye” / ocular analog of cerebral stroke (chen2024centralretinalartery pages 1-2, fawzi2020retinalandophthalmic pages 15-17)
• Historically/related term for transient monocular vision loss: “amaurosis fugax”; The Lancet review recommends “retinal TIA” terminology for transient events. (scott2020retinalvascularocclusions pages 3-4)

1.4 Evidence-source type

This report synthesizes: - Aggregated disease-level resources and guidelines (AAO Preferred Practice Pattern; reviews) (fawzi2020retinalandophthalmic pages 13-15, chen2024centralretinalartery pages 1-2) - Population-level administrative claims epidemiology (Korea HIRA incidence) (park2024incidenceratesof pages 2-4, park2024incidenceratesof pages 1-2) - Cohorts/meta-analyses for systemic risk and treatment evidence (pothikamjorn2025incidenceandrisk pages 4-5, huang2023efficacyandsafety pages 1-3) - ClinicalTrials.gov registry records for trials (NCT04526951 chunk 1, NCT04965038 chunk 1)

2. Etiology

2.1 Primary causal factors

CRAO is predominantly a thromboembolic phenomenon. The AAO PPP states central retinal artery occlusions are commonly embolic. (fawzi2020retinalandophthalmic pages 13-15)

A 2024 Eye review summarizes embolic/thrombotic occlusion as the most implicated mechanism and notes approximately 55% of patients in one study had an identifiable embolic source. (chen2024centralretinalartery pages 2-4)

Arteritic CRAO is a distinct inflammatory entity, most often due to giant cell arteritis (GCA), requiring urgent systemic therapy to prevent bilateral blindness and other ischemic complications. (daxer2024aetiologydiagnosisand pages 1-2, fawzi2020retinalandophthalmic pages 15-17)

2.2 Risk factors (2023–2024 evidence prioritized)

Atherosclerotic and cardioembolic risk - Traditional vascular risk factors (advanced age, male sex, smoking, cardiovascular disease) overlap strongly with ischemic stroke/MI risk factors. (chen2024centralretinalartery pages 2-4) - Carotid disease is a frequent source: among non-arteritic CRAO patients undergoing cervical vessel imaging, 71% had an ipsilateral carotid plaque in one cohort summarized in a 2024 review. (yu2024retinalarteryocclusion pages 1-2) - Severe carotid stenosis: one review cites ~18% of CRAO patients having internal carotid stenosis >80% in a study. (tiwari2024areviewof pages 3-4)

Atrial fibrillation and cardiac disease - A 2025 systematic review/meta-analysis of retinal artery occlusion (RAO) found atrial fibrillation associated with ischemic cerebrovascular disease after RAO (OR 1.32, 95% CI 1.12–1.55). (pothikamjorn2025incidenceandrisk pages 4-5) - Narrative review evidence also emphasizes atrial fibrillation and valvular disease as important embolic sources for CRAO. (daxer2024aetiologydiagnosisand pages 2-3)

Hypercoagulable/hematologic and inflammatory disorders (selected examples) Recent reviews highlight CRAO associations with antiphospholipid syndrome and inherited thrombophilias as less common but relevant in younger/atypical cases. (tiwari2024areviewof pages 2-3, tiwari2024areviewof pages 4-6) - Suggested gene-level entities (risk, not disease-causal for CRAO): F5 (Factor V Leiden), PROC, PROS1.

Inflammation and biomarker evidence (human cohort) A 2023 retrospective cohort reported CRAO patients had higher inflammatory markers (median NLR 2.18 vs 1.94; hs-CRP 1.20 vs 0.83 mg/L) and CRAO independently predicted MACCE (HR 2.321, 95% CI 1.439–3.744). NLR (HR 1.275) and hs-CRP (HR 1.021) were also independent predictors. (chen2023sexdifferencesin pages 3-4, chen2023sexdifferencesin pages 2-3)

2.3 Protective factors

• Cilioretinal artery presence can preserve macular perfusion in some cases (“cilioretinal sparing”), improving the chance of retained central vision. Reported prevalence varies by series (e.g., 5–30% in one review; ~20–25% in another). (chen2024centralretinalartery pages 2-4, tiwari2024areviewof pages 2-3)

2.4 Gene–environment interactions

Direct CRAO-specific gene–environment interaction studies were not identified in the retrieved evidence. Clinically, inherited thrombophilia risk (e.g., Factor V Leiden) is typically considered in conjunction with acquired prothrombotic exposures (e.g., smoking, estrogen therapy, systemic inflammation) as part of individualized risk assessment. (chen2024centralretinalartery pages 4-4, tiwari2024areviewof pages 4-6)

3. Phenotypes (clinical presentation; HPO suggestions)

3.1 Core phenotypes

Acute symptoms/signs - Sudden, painless monocular vision loss (often profound). (chen2024centralretinalartery pages 1-2, fawzi2020retinalandophthalmic pages 8-10) - Relative afferent pupillary defect (RAPD). (daxer2024aetiologydiagnosisand pages 1-2, fawzi2020retinalandophthalmic pages 10-13)

Fundus and imaging phenotypes (with frequencies from 2024 review) Fundus findings reported in CRAO include: cherry-red spot 90%, posterior pole retinal opacity 58%, disc pallor 39%, retinal artery attenuation 32%, disc edema 22%, box-carring 19%; intra-arterial emboli visible in ~20%. (chen2024centralretinalartery pages 2-4)

OCT/OCT-A phenotypes - Acute inner retinal hyperreflectivity and thickening evolving to inner retinal thinning/atrophy. (chen2024centralretinalartery pages 4-4, daxer2024aetiologydiagnosisand pages 5-7) - Paracentral acute middle maculopathy (PAMM) in milder/early cases. (chen2024centralretinalartery pages 2-4)

3.2 Subtypes / clinical entities

• Non-arteritic CRAO (most common; typically embolic) vs arteritic CRAO (often GCA). (lakkis2025centralretinalartery pages 3-5, daxer2024aetiologydiagnosisand pages 1-2)
• Incomplete, subtotal, total CRAO classifications used clinically and in imaging-based classification schemes. (chen2024centralretinalartery pages 2-4)

3.3 Phenotype characteristics

• Onset: acute (seconds to minutes) (fawzi2020retinalandophthalmic pages 10-13)
• Progression: rapid ischemic injury; potential reperfusion but typically poor visual recovery (yu2024retinalarteryocclusion pages 1-2)
• Lateralization: typically unilateral; bilateral CRAO is uncommon (<2% noted in narrative review). (daxer2024aetiologydiagnosisand pages 2-3)

3.4 Quality of life impact

CRAO is associated with severe functional visual impairment (often ≤ counting fingers) and reduced quality of life, consistent with its characterization as catastrophic ophthalmic emergency. (liu2023progressincentral pages 1-3, tiwari2024areviewof pages 2-3)

3.5 Suggested HPO terms (non-exhaustive)

• Sudden visual loss (HP:0000529)
• Monocular visual loss (HP:0030680)
• Scotoma (HP:0000587) (central/centrocecal scotomas noted clinically) (chen2024centralretinalartery pages 2-4)
• Relative afferent pupillary defect (HP:0000611) (daxer2024aetiologydiagnosisand pages 1-2)
• Cherry red spot of the macula (HP:0001103) (daxer2024aetiologydiagnosisand pages 1-2, chen2024centralretinalartery pages 2-4)

4. Genetic / molecular information

4.1 Causal genes

CRAO is typically not a monogenic disorder. No CRAO-causal genes were identified in the retrieved clinical reviews/guidelines.

4.2 Pathogenic variants / susceptibility loci

No CRAO-specific pathogenic variants were identified in the retrieved evidence. Genetic testing is not standard for typical older atherosclerotic CRAO.

4.3 Modifier genes and molecular risk pathways (clinical relevance)

While CRAO is not genetic in the Mendelian sense, hypercoagulability evaluation in selected patients may involve heritable thrombophilia entities (e.g., Factor V Leiden) as clinical risk modifiers. (chen2024centralretinalartery pages 4-4, tiwari2024areviewof pages 4-6)

4.4 Epigenetics / omics

No CRAO-specific epigenomic, transcriptomic, proteomic, or metabolomic signatures were identified in the retrieved evidence. Reviews suggest RAO ocular proteomics remains under-studied. (scott2020retinalvascularocclusions pages 3-4)

5. Environmental information

5.1 Environmental and lifestyle contributors

Environmental/lifestyle factors align with vascular risk: smoking and cardiometabolic risk factors are repeatedly emphasized in CRAO risk profiles. (chen2024centralretinalartery pages 2-4, lakkis2025centralretinalartery pages 2-3)

5.2 Infectious agents

No specific infectious agents were identified as common CRAO triggers in the retrieved evidence; rare infective vegetations are described as uncommon embolic sources in narrative review. (daxer2024aetiologydiagnosisand pages 2-3)

6. Mechanism / pathophysiology

6.1 Causal chain (trigger → tissue injury → phenotype)

1) Upstream trigger: embolus/thrombus (carotid/cardiac) or inflammatory luminal narrowing (GCA) occludes CRA. (chen2024centralretinalartery pages 2-4, daxer2024aetiologydiagnosisand pages 1-2) 2) Immediate consequence: abrupt hypoperfusion of inner retina (CRA supplies inner layers), with minimal collateralization at the arteriolar level. (yu2024retinalarteryocclusion pages 1-2, lakkis2025centralretinalartery pages 2-3) 3) Cellular injury: rapid ischemic damage; experimental and clinical syntheses emphasize extreme time sensitivity—full reversal may be possible if perfusion restored within ~97 minutes, with partial recovery up to 240 minutes in some summaries; other reviews cite very rapid irreversible injury in complete occlusion scenarios. (chen2024centralretinalartery pages 2-4) 4) Clinical manifestation: sudden profound vision loss; fundus whitening and cherry-red spot; OCT evidence of inner retinal edema then atrophy. (chen2024centralretinalartery pages 2-4, daxer2024aetiologydiagnosisand pages 5-7) 5) Downstream sequelae: retinal atrophy; in some patients, ocular neovascularization/neovascular glaucoma weeks later. (chen2024centralretinalartery pages 5-6, fawzi2020retinalandophthalmic pages 15-17)

6.2 Immune and inflammatory involvement

Inflammation is mechanistically central in arteritic CRAO (GCA) and may contribute to systemic risk, with inflammatory biomarkers (NLR, hs-CRP) predicting MACCE in a CRAO cohort. (chen2023sexdifferencesin pages 2-3, daxer2024aetiologydiagnosisand pages 1-2)

6.3 Suggested ontology mappings

GO biological process (examples) - Response to hypoxia (GO:0001666) - Neuron apoptotic process (GO:0051402) - Inflammatory response (GO:0006954) - Angiogenesis (GO:0001525) (for neovascular complications)

Cell types (CL; examples) - Retinal ganglion cell (CL:0000740) - Retinal endothelial cell (CL:0002395) - Microglial cell (CL:0000129) (relevant to ischemia models)

7. Anatomical structures affected

7.1 Organ/tissue/cell targets

• Primary organ: eye/retina—inner retinal layers supplied by CRA. (yu2024retinalarteryocclusion pages 1-2)
• Key structures: central retinal artery; superficial and deep capillary plexuses (OCT-A flow reduction). (chen2024centralretinalartery pages 4-4)

UBERON suggestions - Retina (UBERON:0000966) - Central retinal artery (UBERON term exists; exact ID not retrieved in this run) - Optic nerve head (UBERON:0000972)

7.2 Localization

Typically unilateral; bilateral cases are rare. (daxer2024aetiologydiagnosisand pages 2-3)

8. Temporal development

8.1 Onset

• Acute onset pattern, often sudden. (fawzi2020retinalandophthalmic pages 10-13)

8.2 Progression and stages

• Early phase: retinal edema/whitening; OCT inner retinal thickening and hyperreflectivity; sometimes PAMM in milder disease. (chen2024centralretinalartery pages 4-4, chen2024centralretinalartery pages 2-4)
• Chronic phase: inner retinal thinning/atrophy and optic atrophy; possible rubeosis/neovascular complications. (daxer2024aetiologydiagnosisand pages 5-7, fawzi2020retinalandophthalmic pages 15-17)

8.3 Critical periods

The therapeutic opportunity is time-limited and analogized to stroke reperfusion windows; multiple sources emphasize very early reperfusion as the key determinant for any chance of meaningful visual rescue. (huang2023efficacyandsafety pages 1-3, chen2024centralretinalartery pages 2-4)

9. Inheritance and population

9.1 Epidemiology

A 2024 nationwide South Korean claims study (HIRA) reported: - 10,451 incident CRAO cases (2011–2020) - Weighted mean CRAO incidence 2.10/100,000 person-years (95% CI 2.06–2.14) - Male predominance (60.6% male; male:female incidence ratio ~1.54) - Incidence rises with age and peaks at ages 80–85 years (park2024incidenceratesof pages 2-4, park2024incidenceratesof pages 1-2, park2024incidenceratesof pages 8-10)

A 2023 narrative review summarizes similar age-adjusted incidence estimates across countries (e.g., ~1.87–2.7 per 100,000 person-years all ages, markedly higher in >80 years). (liu2023progressincentral pages 1-3)

9.2 Demographics

Population-level evidence shows higher incidence in men and steep age gradient with older age groups at highest risk. (park2024incidenceratesof pages 2-4)

9.3 Genetic etiology and inheritance

CRAO is predominantly multifactorial (vascular) rather than inherited Mendelian disease.

10. Diagnostics

10.1 Clinical diagnosis

Diagnosis is based on acute clinical presentation plus fundus and multimodal imaging; early fundus may be subtle, so OCT/OCT-A can assist early detection. (yu2024retinalarteryocclusion pages 2-4, daxer2024aetiologydiagnosisand pages 5-7)

10.2 Imaging and functional tests

• Fundus photography/exam: cherry-red spot, retinal whitening, arterial attenuation, box-carring, visible embolus (minority). (chen2024centralretinalartery pages 2-4, yu2024retinalarteryocclusion pages 2-4)
• OCT: inner retinal hyperreflectivity/thickening acutely; thinning chronically. (daxer2024aetiologydiagnosisand pages 5-7, yu2024retinalarteryocclusion pages 2-4)
• OCT-A: reduced flow in superficial/deep plexuses; can quantify reduced vessel density and nonperfusion. (chen2024centralretinalartery pages 4-4, yu2024retinalarteryocclusion pages 4-5)
• Fluorescein angiography (FFA): delayed/absent arterial filling; used to classify incomplete/subtotal/total CRAO; helpful if diagnosis uncertain. (chen2024centralretinalartery pages 2-4, daxer2024aetiologydiagnosisand pages 5-7)
• ERG: preserved a-wave with reduced/absent b-wave in CRAO (inner retinal dysfunction). (daxer2024aetiologydiagnosisand pages 5-7)

10.3 Recommended systemic workup (real-world implementation)

Multiple reviews and the AAO PPP recommend urgent systemic evaluation similar to TIA/stroke pathways, including: - Carotid/vascular imaging (duplex ultrasound) (chen2024centralretinalartery pages 4-4, daxer2024aetiologydiagnosisand pages 5-7) - Cardiac evaluation (echocardiography; Holter for paroxysmal AF) (chen2024centralretinalartery pages 4-4, daxer2024aetiologydiagnosisand pages 5-7) - Neuroimaging due to concurrent cerebral ischemia risk (chen2024centralretinalartery pages 4-4) - Labs for vascular risk (lipids, HbA1c) and, in younger/atypical cases, hypercoagulability/vasculitis testing (protein C/S, factor V Leiden, antiphospholipid antibodies; ANA/ANCA, etc.). (chen2024centralretinalartery pages 4-4, daxer2024aetiologydiagnosisand pages 5-7) - In patients >50 with suspected arteritis, urgent ESR/CRP/CBC and immediate corticosteroids when appropriate. (fawzi2020retinalandophthalmic pages 15-17, daxer2024aetiologydiagnosisand pages 5-7)

Visual evidence (workup table and classification figure): Chen et al. provide a classification figure and a “suggested history and investigations” table. (chen2024centralretinalartery media 966201bd, chen2024centralretinalartery media 2cd88d0e)

10.4 Differential diagnosis

Includes transient monocular visual loss (“retinal TIA”), ocular ischemic syndromes, retinal vein occlusion, optic neuropathies, and inflammatory arteritic ischemia (GCA). (scott2020retinalvascularocclusions pages 3-4, daxer2024aetiologydiagnosisand pages 5-7)

11. Outcome / prognosis

11.1 Visual outcome

Overall visual prognosis is poor. A 2024 review reports 61% of CRAO patients have presenting vision of counting fingers or worse. (chen2024centralretinalartery pages 1-2)

11.2 Ocular complications

Ocular neovascularization risk is clinically important. One 2024 review reports prevalence 2.5–31.6% with mean onset 8.5 weeks after CRAO. (chen2024centralretinalartery pages 5-6)

11.3 Systemic vascular outcomes

CRAO is associated with increased risk of ischemic stroke and other vascular events. - A 2025 RAO meta-analysis reported pooled ischemic cerebrovascular disease incidence in CRAO of 14.4% (95% CI 11.4–18.0). (pothikamjorn2025incidenceandrisk pages 4-5) - A 2023 CRAO cohort found MACCE incidence higher in CRAO vs controls (23.4% vs 9.9%), with CRAO independently predicting MACCE (HR 2.321). (chen2023sexdifferencesin pages 3-4)

12. Treatment

12.1 Acute treatments (evidence and expert analysis)

No universally guideline-endorsed acute vision-restoring therapy Reviews repeatedly conclude evidence remains insufficient for a single optimal acute management plan. (chen2024centralretinalartery pages 5-6, yu2024retinalarteryocclusion pages 1-2)

Conservative maneuvers (limited benefit) Common approaches include ocular massage and intraocular pressure lowering (acetazolamide, anterior chamber paracentesis), carbogen, vasodilators, etc., but reviews emphasize absence of convincing benefit over natural history in high-quality trials and an average improvement rate ~15–21% in retrospective series. (liu2023progressincentral pages 5-7, tiwari2024areviewof pages 6-7)

Thrombolysis (active area; time-window dependent) - Intra-arterial thrombolysis meta-analysis (2023): VA improvement 56% vs 32% in controls (OR 3.55), with greater benefit within 6 hours (OR 4.60). Safety signals include symptomatic intracranial hemorrhage and ischemic stroke/TIA events. (huang2023efficacyandsafety pages 1-3, huang2023efficacyandsafety pages 8-9) - Single-center stroke-center experience (2024): IVT used rarely (3.55%); ≥2-line improvement 25% after IVT; symptomatic intracranial hemorrhage 1/13 (7.6%); no 3-month VA difference versus matched conservative controls. (alhayek2024thrombolytictherapyfor pages 1-2)

Hyperbaric oxygen therapy (HBOT) Evidence is mixed: case series report logMAR improvements with complications (e.g., barotrauma), while a recent meta-analytic conclusion cited in a 2024 review is that HBOT “does not improve final visual outcomes” and carries risks. (liu2023progressincentral pages 5-7, chen2024centralretinalartery pages 5-6)

Laser embolysis (Nd:YAG) and surgical approaches Nd:YAG embolysis may help selected patients with visible emboli, but applicability is limited and hemorrhagic complications occur; vitrectomy-based and endovascular/vitreoretinal approaches are emerging but lack robust comparative outcome data in the retrieved excerpts. (liu2023progressincentral pages 5-7, yu2024retinalarteryocclusion pages 10-12)

Subacute ocular complication management Pan-retinal photocoagulation (PRP) ± intravitreal anti-VEGF is recommended for iris/retinal neovascularization per AAO PPP. (fawzi2020retinalandophthalmic pages 13-15)

12.2 Secondary prevention (real-world implementation)

Given stroke-equivalent framing, secondary prevention mirrors TIA/minor stroke practice in many pathways. A 2024 review states guidelines support early antiplatelet therapy (e.g., initial dual therapy for 21 days then long-term single agent, typically aspirin 81 mg). (chen2024centralretinalartery pages 5-6)

12.3 Clinical trials (ongoing/recent)

TenCRAOS (NCT04526951) - Phase 3, randomized, double-blind, double-dummy; tenecteplase 0.25 mg/kg IV bolus vs aspirin 300 mg within 4.5 hours. - Primary outcome: proportion achieving ≤0.7 logMAR at 30 days. - Outcomes include safety (intracranial hemorrhage, systemic bleeding) and QoL (NEI-VFQ-25; EQ-5D). (NCT04526951 chunk 1)

REVISION (NCT04965038) - Phase 3, randomized, placebo-controlled, quadruple-masked; tenecteplase within 4.5 hours; enrollment 422. - Primary outcome: BCVA LogMAR ≤0.5 at 30 days. - Secondary outcomes: OCTA/FFA perfusion, MRI ischemic lesions, NIHSS/mRS, hemorrhagic complications, mortality. (NCT04965038 chunk 1)

Selective intra-arterial thrombolysis (NCT05562284) - Nonrandomized open-label; super-selective IAT with alteplase vs conservative (including HBOT); symptom duration ≤7 days. - Primary outcome: Humphrey visual-field indices at 3 months. (NCT05562284 chunk 1)

12.4 MAXO suggestions (examples)

• Intravenous thrombolysis (MAXO term: thrombolytic therapy)
• Intra-arterial thrombolysis (MAXO: endovascular thrombolysis)
• Hyperbaric oxygen therapy (MAXO: hyperbaric oxygen therapy)
• Carotid ultrasonography (MAXO: diagnostic ultrasound)
• Dual antiplatelet therapy (MAXO: antiplatelet therapy)
• Pan-retinal photocoagulation (MAXO: photocoagulation therapy)

13. Prevention

13.1 Primary prevention

Primary prevention aligns with cardiovascular risk reduction (smoking cessation, blood pressure and lipid control, diabetes management) due to shared causal pathways with ischemic stroke. (chen2024centralretinalartery pages 2-4)

13.2 Secondary prevention

Urgent stroke-center evaluation and initiation of appropriate antithrombotic therapy and risk-factor management aim to prevent early recurrent ischemic events; AAO PPP emphasizes highest stroke risk in the first 1–4 weeks, especially first 7 days. (fawzi2020retinalandophthalmic pages 13-15, fawzi2020retinalandophthalmic pages 15-17)

13.3 Tertiary prevention

Monitoring and treating ocular neovascularization (PRP ± anti-VEGF) reduces risk of neovascular glaucoma. (fawzi2020retinalandophthalmic pages 13-15)

14. Other species / natural disease

No naturally occurring CRAO epidemiology in non-human species was identified in the retrieved evidence; the available evidence primarily concerns induced experimental models.

15. Model organisms / experimental models

A 2019 comprehensive review summarizes 88 experiments across six species (rodents most common; monkeys second) to model RAO/CRAO, with key conclusions: - Best anatomical similarity to humans: nonhuman primates, then pigs. (vestergaard2019animalmodelsused pages 1-2) - Most common induction methods: laser-induced occlusion and arterial ligation/clamping; other methods include raised intraocular pressure, vasoconstrictors, embolization, and endovascular techniques. (vestergaard2019animalmodelsused pages 1-2) - Major limitation: most experimental occlusions last 30–90 minutes and are followed by reperfusion, whereas human CRAO may be longer lasting; endovascular approaches may produce more permanent occlusion. (vestergaard2019animalmodelsused pages 1-2, vestergaard2019animalmodelsused pages 7-8)

These models are used to study ischemic retinal injury mechanisms, reperfusion biology, inflammatory responses, and candidate neuroprotective/reperfusion interventions, but careful validation and awareness of collateral damage/reperfusion are necessary for translational relevance. (vestergaard2019animalmodelsused pages 8-10)

Expert opinions and authoritative-source synthesis (interpretation)

1) Stroke-equivalent framing is now mainstream in ophthalmology and neuro-ophthalmology: CRAO should be treated as acute retinal arterial ischemia requiring urgent systemic workup at a stroke center. (chen2024centralretinalartery pages 1-2, fawzi2020retinalandophthalmic pages 15-17) 2) Evidence gap for acute vision rescue remains the main unmet need: conservative maneuvers are not reliably effective; thrombolysis shows time-dependent signals but is limited by delays, heterogeneity, and safety concerns; multiple phase 3 trials are designed to address this. (huang2023efficacyandsafety pages 1-3, NCT04965038 chunk 1) 3) Secondary prevention is actionable now: early vascular evaluation and antithrombotic/risk-factor management are recommended to reduce early stroke risk and longer-term MACCE risk. (chen2024centralretinalartery pages 5-6, chen2023sexdifferencesin pages 3-4)

URLs and publication dates (selected core sources)

• Chen C. et al. 2024-03. Eye. “Central retinal artery occlusion: a stroke of the eye.” https://doi.org/10.1038/s41433-024-03029-w (chen2024centralretinalartery pages 1-2)
• Park S.H. et al. 2024-03. BMC Ophthalmology. Korea nationwide incidence study. https://doi.org/10.1186/s12886-024-03397-7 (park2024incidenceratesof pages 2-4)
• Huang L. et al. 2023-08. Graefe’s Arch Clin Exp Ophthalmol. IAT meta-analysis. https://doi.org/10.1007/s00417-022-05797-1 (huang2023efficacyandsafety pages 1-3)
• Alhayek N. et al. 2024-01. Neuro-Ophthalmology. Stroke-center thrombolysis experience. https://doi.org/10.1080/01658107.2023.2290536 (alhayek2024thrombolytictherapyfor pages 1-2)
• AAO Preferred Practice Pattern. Fawzi A. et al. 2020-02. Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.09.028 (fawzi2020retinalandophthalmic pages 13-15)
• Chen T. et al. 2023-09. Scientific Reports. MACCE risk and biomarkers. https://doi.org/10.1038/s41598-023-42247-2 (chen2023sexdifferencesin pages 3-4)
• TenCRAOS trial registry: ClinicalTrials.gov NCT04526951 (updated metadata shown in excerpt). https://clinicaltrials.gov/study/NCT04526951 (NCT04526951 chunk 1)
• REVISION trial registry: ClinicalTrials.gov NCT04965038. https://clinicaltrials.gov/study/NCT04965038 (NCT04965038 chunk 1)

References

1. (chen2024centralretinalartery pages 1-2): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

2. (chen2024centralretinalartery pages 4-4): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

3. (fawzi2020retinalandophthalmic pages 15-17): A. Fawzi, Steven T. Bailey, Jennifer I. Lim, Gui-shang Ying, Robert S. Feder, R. Chuck, Steven P. Dunn, C. Flaxel, S. Gedde, Francis S. Mah, Randall J. Olson, David K. Wallace, and D. Musch. Retinal and ophthalmic artery occlusions preferred practice pattern®. Ophthalmology, 127:P259-P287, Feb 2020. URL: https://doi.org/10.1016/j.ophtha.2019.09.028, doi:10.1016/j.ophtha.2019.09.028. This article has 170 citations and is from a highest quality peer-reviewed journal.

4. (park2024incidenceratesof pages 2-4): Shin Hyeong Park, Bum Jun Kim, Ji Hye Kim, Seung Chan Kim, Rock Bum Kim, and Yong Seop Han. Incidence rates of retinal vascular occlusive diseases from 2011 to 2020 in south korea: a nationwide cohort study. BMC Ophthalmology, Mar 2024. URL: https://doi.org/10.1186/s12886-024-03397-7, doi:10.1186/s12886-024-03397-7. This article has 10 citations and is from a peer-reviewed journal.

5. (park2024incidenceratesof pages 1-2): Shin Hyeong Park, Bum Jun Kim, Ji Hye Kim, Seung Chan Kim, Rock Bum Kim, and Yong Seop Han. Incidence rates of retinal vascular occlusive diseases from 2011 to 2020 in south korea: a nationwide cohort study. BMC Ophthalmology, Mar 2024. URL: https://doi.org/10.1186/s12886-024-03397-7, doi:10.1186/s12886-024-03397-7. This article has 10 citations and is from a peer-reviewed journal.

6. (park2024incidenceratesof pages 8-10): Shin Hyeong Park, Bum Jun Kim, Ji Hye Kim, Seung Chan Kim, Rock Bum Kim, and Yong Seop Han. Incidence rates of retinal vascular occlusive diseases from 2011 to 2020 in south korea: a nationwide cohort study. BMC Ophthalmology, Mar 2024. URL: https://doi.org/10.1186/s12886-024-03397-7, doi:10.1186/s12886-024-03397-7. This article has 10 citations and is from a peer-reviewed journal.

7. (tiwari2024areviewof pages 2-3): Varun Tiwari, Simerjeet Singh J Bagga, Roshan Prasad, and Swapneel Mathurkar. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.55814, doi:10.7759/cureus.55814. This article has 12 citations.

8. (liu2023progressincentral pages 1-3): Weishai Liu, Dan Bai, and Lieling Kou. Progress in central retinal artery occlusion: a narrative review. The Journal of International Medical Research, Sep 2023. URL: https://doi.org/10.1177/03000605231198388, doi:10.1177/03000605231198388. This article has 23 citations.

9. (pothikamjorn2025incidenceandrisk pages 4-5): Thananop Pothikamjorn, Chutibhorn Charnnarong, Paweena Susantitaphong, and Supharat Jariyakosol. Incidence and risk factors associated with ischemic cerebrovascular disease in patients with retinal artery occlusion: a systematic review and meta-analysis. Scientific Reports, Sep 2025. URL: https://doi.org/10.1038/s41598-025-18419-7, doi:10.1038/s41598-025-18419-7. This article has 1 citations and is from a peer-reviewed journal.

10. (alhayek2024thrombolytictherapyfor pages 1-2): Nour Alhayek, Jacob M. Sobczak, Aimen Vanood, Cumara B. O’Carroll, Bart M. Demaerschalk, John Chen, and Oana M. Dumitrascu. Thrombolytic therapy for central retinal artery occlusion in an academic multi-site stroke centre. Neuro-Ophthalmology, 48:111-121, Jan 2024. URL: https://doi.org/10.1080/01658107.2023.2290536, doi:10.1080/01658107.2023.2290536. This article has 3 citations and is from a peer-reviewed journal.

11. (huang2023efficacyandsafety pages 1-3): Lele Huang, Yujie Wang, and Ruijun Zhang. Efficacy and safety of intra-arterial thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 261:103-113, Aug 2023. URL: https://doi.org/10.1007/s00417-022-05797-1, doi:10.1007/s00417-022-05797-1. This article has 20 citations.

12. (huang2023efficacyandsafety pages 8-9): Lele Huang, Yujie Wang, and Ruijun Zhang. Efficacy and safety of intra-arterial thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 261:103-113, Aug 2023. URL: https://doi.org/10.1007/s00417-022-05797-1, doi:10.1007/s00417-022-05797-1. This article has 20 citations.

13. (chen2024centralretinalartery pages 5-6): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

14. (chen2024centralretinalartery pages 2-4): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

15. (tiwari2024areviewof pages 4-6): Varun Tiwari, Simerjeet Singh J Bagga, Roshan Prasad, and Swapneel Mathurkar. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.55814, doi:10.7759/cureus.55814. This article has 12 citations.

16. (daxer2024aetiologydiagnosisand pages 5-7): Barbara Daxer, Wolfgang Radner, Florian Fischer, Andreea-Liliana Cocoșilă, and Armin Ettl. Aetiology, diagnosis and treatment of arterial occlusions of the retina—a narrative review. Medicina, 60:526, Mar 2024. URL: https://doi.org/10.3390/medicina60040526, doi:10.3390/medicina60040526. This article has 12 citations.

17. (yu2024retinalarteryocclusion pages 2-4): Hannah J. Yu, Sophia Choi, Rodney Guiseppi, and Touka Banaee. Retinal artery occlusion: a review of current management practices. Journal of Ophthalmic and Vision Research, 19:488-507, Dec 2024. URL: https://doi.org/10.18502/jovr.v19i4.16559, doi:10.18502/jovr.v19i4.16559. This article has 7 citations and is from a peer-reviewed journal.

18. (fawzi2020retinalandophthalmic pages 8-10): A. Fawzi, Steven T. Bailey, Jennifer I. Lim, Gui-shang Ying, Robert S. Feder, R. Chuck, Steven P. Dunn, C. Flaxel, S. Gedde, Francis S. Mah, Randall J. Olson, David K. Wallace, and D. Musch. Retinal and ophthalmic artery occlusions preferred practice pattern®. Ophthalmology, 127:P259-P287, Feb 2020. URL: https://doi.org/10.1016/j.ophtha.2019.09.028, doi:10.1016/j.ophtha.2019.09.028. This article has 170 citations and is from a highest quality peer-reviewed journal.

19. (fawzi2020retinalandophthalmic pages 22-26): A. Fawzi, Steven T. Bailey, Jennifer I. Lim, Gui-shang Ying, Robert S. Feder, R. Chuck, Steven P. Dunn, C. Flaxel, S. Gedde, Francis S. Mah, Randall J. Olson, David K. Wallace, and D. Musch. Retinal and ophthalmic artery occlusions preferred practice pattern®. Ophthalmology, 127:P259-P287, Feb 2020. URL: https://doi.org/10.1016/j.ophtha.2019.09.028, doi:10.1016/j.ophtha.2019.09.028. This article has 170 citations and is from a highest quality peer-reviewed journal.

20. (yu2024retinalarteryocclusion pages 1-2): Hannah J. Yu, Sophia Choi, Rodney Guiseppi, and Touka Banaee. Retinal artery occlusion: a review of current management practices. Journal of Ophthalmic and Vision Research, 19:488-507, Dec 2024. URL: https://doi.org/10.18502/jovr.v19i4.16559, doi:10.18502/jovr.v19i4.16559. This article has 7 citations and is from a peer-reviewed journal.

21. (scott2020retinalvascularocclusions pages 3-4): Ingrid U Scott, Peter A Campochiaro, Nancy J Newman, and Valérie Biousse. Retinal vascular occlusions. The Lancet, 396:1927-1940, Dec 2020. URL: https://doi.org/10.1016/s0140-6736(20)31559-2, doi:10.1016/s0140-6736(20)31559-2. This article has 300 citations and is from a highest quality peer-reviewed journal.

22. (fawzi2020retinalandophthalmic pages 13-15): A. Fawzi, Steven T. Bailey, Jennifer I. Lim, Gui-shang Ying, Robert S. Feder, R. Chuck, Steven P. Dunn, C. Flaxel, S. Gedde, Francis S. Mah, Randall J. Olson, David K. Wallace, and D. Musch. Retinal and ophthalmic artery occlusions preferred practice pattern®. Ophthalmology, 127:P259-P287, Feb 2020. URL: https://doi.org/10.1016/j.ophtha.2019.09.028, doi:10.1016/j.ophtha.2019.09.028. This article has 170 citations and is from a highest quality peer-reviewed journal.

23. (NCT04526951 chunk 1): Anne Hege Aamodt. TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS). Oslo University Hospital. 2020. ClinicalTrials.gov Identifier: NCT04526951

24. (NCT04965038 chunk 1): Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion. University Hospital Tuebingen. 2022. ClinicalTrials.gov Identifier: NCT04965038

25. (daxer2024aetiologydiagnosisand pages 1-2): Barbara Daxer, Wolfgang Radner, Florian Fischer, Andreea-Liliana Cocoșilă, and Armin Ettl. Aetiology, diagnosis and treatment of arterial occlusions of the retina—a narrative review. Medicina, 60:526, Mar 2024. URL: https://doi.org/10.3390/medicina60040526, doi:10.3390/medicina60040526. This article has 12 citations.

26. (tiwari2024areviewof pages 3-4): Varun Tiwari, Simerjeet Singh J Bagga, Roshan Prasad, and Swapneel Mathurkar. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.55814, doi:10.7759/cureus.55814. This article has 12 citations.

27. (daxer2024aetiologydiagnosisand pages 2-3): Barbara Daxer, Wolfgang Radner, Florian Fischer, Andreea-Liliana Cocoșilă, and Armin Ettl. Aetiology, diagnosis and treatment of arterial occlusions of the retina—a narrative review. Medicina, 60:526, Mar 2024. URL: https://doi.org/10.3390/medicina60040526, doi:10.3390/medicina60040526. This article has 12 citations.

28. (chen2023sexdifferencesin pages 3-4): Ting Chen, Yuedan Wang, Xuejie Li, Jiaqing Feng, Hongxia Yang, Ying Li, Hui Feng, and Xuan Xiao. Sex differences in major adverse cardiovascular and cerebrovascular event risk among central retinal artery occlusion patients. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42247-2, doi:10.1038/s41598-023-42247-2. This article has 9 citations and is from a peer-reviewed journal.

29. (chen2023sexdifferencesin pages 2-3): Ting Chen, Yuedan Wang, Xuejie Li, Jiaqing Feng, Hongxia Yang, Ying Li, Hui Feng, and Xuan Xiao. Sex differences in major adverse cardiovascular and cerebrovascular event risk among central retinal artery occlusion patients. Scientific Reports, Sep 2023. URL: https://doi.org/10.1038/s41598-023-42247-2, doi:10.1038/s41598-023-42247-2. This article has 9 citations and is from a peer-reviewed journal.

30. (fawzi2020retinalandophthalmic pages 10-13): A. Fawzi, Steven T. Bailey, Jennifer I. Lim, Gui-shang Ying, Robert S. Feder, R. Chuck, Steven P. Dunn, C. Flaxel, S. Gedde, Francis S. Mah, Randall J. Olson, David K. Wallace, and D. Musch. Retinal and ophthalmic artery occlusions preferred practice pattern®. Ophthalmology, 127:P259-P287, Feb 2020. URL: https://doi.org/10.1016/j.ophtha.2019.09.028, doi:10.1016/j.ophtha.2019.09.028. This article has 170 citations and is from a highest quality peer-reviewed journal.

31. (lakkis2025centralretinalartery pages 3-5): Toufic Lakkis, Anas Mahmoud Awad Elshoura, Gabriel Andres Soria Behr, Mata Cardenas Eduardo Mauricio, Susana Sil-Zavaleta, Long Yin Cai, and Manju Rai. Central retinal artery occlusion in acute care: current practices and emerging therapies. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.92786, doi:10.7759/cureus.92786. This article has 0 citations.

32. (lakkis2025centralretinalartery pages 2-3): Toufic Lakkis, Anas Mahmoud Awad Elshoura, Gabriel Andres Soria Behr, Mata Cardenas Eduardo Mauricio, Susana Sil-Zavaleta, Long Yin Cai, and Manju Rai. Central retinal artery occlusion in acute care: current practices and emerging therapies. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.92786, doi:10.7759/cureus.92786. This article has 0 citations.

33. (yu2024retinalarteryocclusion pages 4-5): Hannah J. Yu, Sophia Choi, Rodney Guiseppi, and Touka Banaee. Retinal artery occlusion: a review of current management practices. Journal of Ophthalmic and Vision Research, 19:488-507, Dec 2024. URL: https://doi.org/10.18502/jovr.v19i4.16559, doi:10.18502/jovr.v19i4.16559. This article has 7 citations and is from a peer-reviewed journal.

34. (chen2024centralretinalartery media 966201bd): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

35. (chen2024centralretinalartery media 2cd88d0e): Celia Chen, Gurfarmaan Singh, Reema Madike, and Sudha Cugati. Central retinal artery occlusion: a stroke of the eye. Eye, 38:2319-2326, Mar 2024. URL: https://doi.org/10.1038/s41433-024-03029-w, doi:10.1038/s41433-024-03029-w. This article has 43 citations and is from a peer-reviewed journal.

36. (liu2023progressincentral pages 5-7): Weishai Liu, Dan Bai, and Lieling Kou. Progress in central retinal artery occlusion: a narrative review. The Journal of International Medical Research, Sep 2023. URL: https://doi.org/10.1177/03000605231198388, doi:10.1177/03000605231198388. This article has 23 citations.

37. (tiwari2024areviewof pages 6-7): Varun Tiwari, Simerjeet Singh J Bagga, Roshan Prasad, and Swapneel Mathurkar. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment. Cureus, Mar 2024. URL: https://doi.org/10.7759/cureus.55814, doi:10.7759/cureus.55814. This article has 12 citations.

38. (yu2024retinalarteryocclusion pages 10-12): Hannah J. Yu, Sophia Choi, Rodney Guiseppi, and Touka Banaee. Retinal artery occlusion: a review of current management practices. Journal of Ophthalmic and Vision Research, 19:488-507, Dec 2024. URL: https://doi.org/10.18502/jovr.v19i4.16559, doi:10.18502/jovr.v19i4.16559. This article has 7 citations and is from a peer-reviewed journal.

39. (NCT05562284 chunk 1): Ping Fei. Safety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. 2022. ClinicalTrials.gov Identifier: NCT05562284

40. (vestergaard2019animalmodelsused pages 1-2): Nanna Vestergaard, Lasse Jørgensen Cehofski, Bent Honoré, Kristian Aasbjerg, and Henrik Vorum. Animal models used to simulate retinal artery occlusion: a comprehensive review. Translational Vision Science & Technology, 8:23, Aug 2019. URL: https://doi.org/10.1167/tvst.8.4.23, doi:10.1167/tvst.8.4.23. This article has 25 citations and is from a peer-reviewed journal.

41. (vestergaard2019animalmodelsused pages 7-8): Nanna Vestergaard, Lasse Jørgensen Cehofski, Bent Honoré, Kristian Aasbjerg, and Henrik Vorum. Animal models used to simulate retinal artery occlusion: a comprehensive review. Translational Vision Science & Technology, 8:23, Aug 2019. URL: https://doi.org/10.1167/tvst.8.4.23, doi:10.1167/tvst.8.4.23. This article has 25 citations and is from a peer-reviewed journal.

42. (vestergaard2019animalmodelsused pages 8-10): Nanna Vestergaard, Lasse Jørgensen Cehofski, Bent Honoré, Kristian Aasbjerg, and Henrik Vorum. Animal models used to simulate retinal artery occlusion: a comprehensive review. Translational Vision Science & Technology, 8:23, Aug 2019. URL: https://doi.org/10.1167/tvst.8.4.23, doi:10.1167/tvst.8.4.23. This article has 25 citations and is from a peer-reviewed journal.